Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.05.004Source: DataRank Database

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report is a research paper published in Transplantation and Cellular Therapy (2021). On theSindex it has a DataRank of 0.614. It has been cited 59 times.

N/A

0.614DataRank · unranked

Scored on demand from live citation data

Open Access59 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (19 grants)Impact (FWCI 5.51)OA: hybridTopics (26)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.614

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (27)

Daniel R. Couriel ORCID,Aleksandr Lazaryan ORCID,Vijaya Raj Bhatt ORCID,Nataliya P. Buxbaum ORCID,Amin M. Alousi ORCID

Live enrichment

PubMed:34147469 PMC:PMC8944207 OpenAlex:https://openalex.org/W3171632039

Pfizer

Grant: US 20130115232A1

Pfizer

Grant: WO2013066369A3

Intramural NIH HHS

Grant: ZIA BC011743

CTI Biopharma

Government of South Australia

National Institutes of Health

Dana-Farber Cancer Institute

Meiji Seika Pharma

Takeda Pharmaceutical Company

Bristol-Myers Squibb

CareDx

Novartis

Janssen Pharmaceuticals

National Cancer Institute

Sapienza Università di Roma

Amgen

AstraZeneca

Gilead Sciences

Massachusetts General Hospital

FWCI

5.51

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.jtct.2021.05.004

publisherhttps://doi.org/10.1016/j.jtct.2021.05.004

publisherhttps://api.elsevier.com/content/article/PII:S2666636721008952?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666636721008952?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34147469

Fields of Study

Hematopoietic Stem Cell TransplantationChildhood Cancer Survivors' Quality of LifePancreatic function and diabetes

MeSH Terms

Chronic DiseaseClinical Trials as TopicGraft vs Host DiseaseHumansNational Institutes of Health (U.S.)United StatesHematopoietic Stem Cell TransplantationConsensus

Keywords

MedicineClinical trialIntensive care medicineDiseaseContext (archaeology)Graft-versus-host diseaseSystemic therapyChronic diseaseInternal medicineCancerChronic graft-versus-host diseaseConsensusInitial TherapyAllogeneic Hematopoietic Cell TransplantationTreatment Refractory

Sustainable Development Goals

SDG 0: Partnerships for the goals